A Double-Blind, Placebo-Controlled, Dose Ranging Study of Xanamem® in Healthy Elderly Volunteers
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
Xanamem® is being developed as a potential drug for Mild Cognitive Impairment in Alzheimer's
disease. This study drug has been designed to change the cortisol levels in the brain.
Cortisol is a naturally occurring hormone in the body. It is believed that reducing the level
of cortisol will be a benefit in the treatment of Mild Cognitive Impairment in Alzheimer's
disease.
The purpose of this study in older volunteers is to investigate the smallest dose of Xanamem®
(5 mg or 10 mg) which works and to investigate which dose in this study will be used in the
upcoming clinical trials in patients.